Strategic sale CENTOGENE recently completed a strategic transaction with Charme Capital Partners, signaling a potential for restructuring or divestiture opportunities. Sales teams can explore roles in ongoing post-deal integration, asset monetization, or services for the acquiring entity or spun-out entities.

Data assets With a vast genetic database covering 1,000,000 individuals and diagnostics for over 2,500 rare diseases, CENTOGENE offers high-value data and analytics capabilities that could be licensed or partnered for drug development, patient recruitment, and biomarker discovery.

Neurogenetic focus Active involvement in Parkinson’s disease genetics and neurodegenerative research presents opportunities for collaborations in genetic testing, clinical trial enrichment, and companion diagnostics with pharma companies focused on orphan/neurodegenerative programs.

Global reach Centogene operates in over 100 countries, enabling multinational collaboration, regulatory-ready data solutions, and cross-border patient recruitment strategies that can be offered to global biopharma and contract research organizations.

Financial transition Ongoing funding events and recent delisting notice imply a phase of financial reorganization; sales teams can present scalable service contracts, strategic partnerships, or consulting for liquidity optimization, portfolio optimization, and ongoing CRO/diagnostics services.